WO1995015746A1
(en)
*
|
1993-12-10 |
1995-06-15 |
The School Of Pharmacy |
Liposome delivery systems
|
US5931809A
(en)
*
|
1995-07-14 |
1999-08-03 |
Depotech Corporation |
Epidural administration of therapeutic compounds with sustained rate of release
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
US6083910A
(en)
|
1996-12-13 |
2000-07-04 |
Chiron Corporation |
Therapeutic uses of resolved intact or clipped native-sequence PDGF-BB dimers
|
US6511477B2
(en)
*
|
1997-03-13 |
2003-01-28 |
Biocardia, Inc. |
Method of drug delivery to interstitial regions of the myocardium
|
US6443949B2
(en)
*
|
1997-03-13 |
2002-09-03 |
Biocardia, Inc. |
Method of drug delivery to interstitial regions of the myocardium
|
DE69841598D1
(de)
|
1997-09-18 |
2010-05-20 |
Pacira Pharmaceuticals Inc |
Retardierte freisetzung liposmaler anesthetischer zusammensetzungen.
|
BR9813930A
(pt)
|
1997-11-06 |
2006-12-19 |
Chiron Spa |
antìgeno neisserial
|
US20020039596A1
(en)
|
1997-11-14 |
2002-04-04 |
Hartoun Hartounian |
Production of multivesicular liposomes
|
EP1047784B2
(en)
|
1998-01-14 |
2015-03-18 |
Novartis Vaccines and Diagnostics S.r.l. |
Neissera meningitidis antigens
|
NZ532665A
(en)
|
1998-05-01 |
2005-11-25 |
Inst Genomic Research |
Neisseria meningitidis antigens and compositions
|
US6740643B2
(en)
*
|
1999-01-21 |
2004-05-25 |
Mirus Corporation |
Compositions and methods for drug delivery using amphiphile binding molecules
|
CZ20013103A3
(cs)
*
|
1999-03-02 |
2002-01-16 |
The Liposome Company, Inc. |
Způsob zapouzdřování bioaktivních komplexů do liposomů
|
NZ571167A
(en)
|
1999-04-30 |
2010-05-28 |
Novartis Vaccines & Diagnostic |
Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
AUPQ259399A0
(en)
|
1999-09-01 |
1999-09-23 |
Lustre Investments Pte Ltd |
Therapeutic agents
|
EP2975127A1
(en)
|
1999-10-29 |
2016-01-20 |
GlaxoSmithKline Biologicals SA |
Neisserial antigenic peptides
|
JP2003516731A
(ja)
|
1999-11-18 |
2003-05-20 |
カイロン コーポレイション |
ヒトfgf−21遺伝子および遺伝子発現産物
|
US20070219363A1
(en)
*
|
1999-11-29 |
2007-09-20 |
Budker Vladimir G |
Chelating Compound for Drug Delivery
|
BR0016652A
(pt)
|
1999-12-23 |
2002-11-19 |
Neurochem Inc |
Métodos para inibir angiopatia amilóide cerebral, para tratar um estado de doença caracterizado por angiopatia amilóide cerebral em um indivìduo, e para diagnosticar angiopatia amilóide cerebral em um indivìduo
|
EP2275129A3
(en)
|
2000-01-17 |
2013-11-06 |
Novartis Vaccines and Diagnostics S.r.l. |
Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
|
WO2001066595A2
(en)
|
2000-03-08 |
2001-09-13 |
Chiron Corporation |
Human fgf-23 gene and gene expression products
|
EP1950297A2
(en)
|
2000-05-31 |
2008-07-30 |
Novartis Vaccines and Diagnostics, Inc. |
Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
|
US7700359B2
(en)
|
2000-06-02 |
2010-04-20 |
Novartis Vaccines And Diagnostics, Inc. |
Gene products differentially expressed in cancerous cells
|
ATE397094T1
(de)
|
2000-06-15 |
2008-06-15 |
Novartis Vaccines & Diagnostic |
Polynukleotide zur bestimmung von kolonkrebs
|
SG165981A1
(en)
|
2000-10-27 |
2010-11-29 |
Chiron Srl |
Nucleic acids and proteins from streptococcus groups a & b
|
WO2002045713A2
(en)
*
|
2000-12-04 |
2002-06-13 |
Sepracor, Inc. |
Orally-bioavailable formulations of fentanyl and congeners thereof
|
JP2004535765A
(ja)
|
2000-12-07 |
2004-12-02 |
カイロン コーポレイション |
前立腺癌においてアップレギュレートされた内因性レトロウイルス
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
WO2002081639A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
WO2002081641A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
AU2002258728A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
BR0102252B1
(pt)
*
|
2001-04-10 |
2013-10-22 |
|
Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
|
WO2002094871A1
(en)
|
2001-05-24 |
2002-11-28 |
Human Dna Technology Inc |
Novel keratinocyte growth factor-2 analogue in hair follicle
|
FR2827516B1
(fr)
*
|
2001-07-19 |
2003-09-19 |
Servier Lab |
Composition pharmaceutique pour l'administration par voie nasale d'estradiol et de norethisterone
|
BRPI0105509B8
(pt)
*
|
2001-11-05 |
2021-05-25 |
Univ Minas Gerais |
formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
|
EP1487854B1
(en)
|
2001-11-09 |
2010-04-28 |
Georgetown University |
Novel isoform of vascular endothelial cell growth inhibitor (vegi)
|
EP2335723A1
(en)
|
2001-12-12 |
2011-06-22 |
Novartis Vaccines and Diagnostics S.r.l. |
Immunisation against chlamydia trachomatis
|
AU2003235791A1
(en)
|
2002-01-08 |
2003-07-24 |
Chiron Corporation |
Gene products differentially expressed in cancerous breast cells and their methods of use
|
JP2005520543A
(ja)
|
2002-03-21 |
2005-07-14 |
サイグレス ディスカバリー, インコーポレイテッド |
癌における新規組成物および方法
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
EP2302039A1
(en)
|
2002-06-13 |
2011-03-30 |
Novartis Vaccines and Diagnostics, Inc. |
Virus-like particles comprising HML-2 gag polypeptide
|
CN100518831C
(zh)
*
|
2002-08-15 |
2009-07-29 |
刘云清 |
固体纳米药物及其制备方法
|
UA80447C2
(en)
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
PT2279746E
(pt)
|
2002-11-15 |
2013-12-09 |
Novartis Vaccines & Diagnostic |
Proteínas de superfície de neisseria meningitidis
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
PT1575517E
(pt)
|
2002-12-24 |
2012-05-28 |
Rinat Neuroscience Corp |
Anticorpos anti-ngf e métodos de utilização dos mesmos
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
CA2516138A1
(en)
|
2003-02-14 |
2004-09-02 |
Sagres Discovery, Inc. |
Therapeutic gpcr targets in cancer
|
US20040170982A1
(en)
|
2003-02-14 |
2004-09-02 |
Morris David W. |
Novel therapeutic targets in cancer
|
US7767387B2
(en)
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
PL379983A1
(pl)
|
2003-02-19 |
2006-11-27 |
Rinat Neuroscience Corp. |
Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
WO2005023767A2
(en)
|
2003-09-10 |
2005-03-17 |
Brentwood Equities Ltd. |
Diastereomers of 4-aryloxy-3-hydroxypiperidines
|
US7968690B2
(en)
|
2003-12-23 |
2011-06-28 |
Rinat Neuroscience Corp. |
Agonist anti-trkC antibodies and methods using same
|
CN104292321A
(zh)
|
2004-03-29 |
2015-01-21 |
株式会社嘉尔药物 |
新的半乳凝素9 突变体蛋白质及其用途
|
DK2206728T3
(en)
|
2004-04-07 |
2018-04-23 |
Rinat Neuroscience Corp |
METHODS OF TREATING BONE CANCER PAIN BY SUBMITTING A NERVOUS FACTOR-ANTAGONISTIC ANTIBODY
|
KR100896697B1
(ko)
|
2004-04-09 |
2009-05-14 |
(주)아모레퍼시픽 |
고압유화기술에 의한 대황추출물의 경피흡수 촉진방법 및이를 응용한 미백용 피부 외용제 조성물
|
ES2673972T3
(es)
|
2004-07-09 |
2018-06-26 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Formas solubles de la glicoproteína G de los virus hendra y nipah
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
EA016357B1
(ru)
|
2004-07-30 |
2012-04-30 |
Ринат Ньюросайенс Корп. |
Антитела, направленные против бета-амилоидного пептида, и способы их применения
|
US7666442B2
(en)
*
|
2004-08-31 |
2010-02-23 |
Tracie Martyn International, Llc |
Topical compositions comprising benfotiamine and pyridoxamine
|
US7939490B2
(en)
|
2004-12-13 |
2011-05-10 |
University Of Maryland, Baltimore |
TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
|
SG164344A1
(en)
|
2005-02-18 |
2010-09-29 |
Novartis Vaccines & Diagnostics Srl |
Immunogens from uropathogenic escherichia coli
|
EP1865981A2
(en)
|
2005-04-07 |
2007-12-19 |
Chiron Corporation |
Cacna1e in cancer diagnosis, detection and treatment
|
EP1871911A2
(en)
|
2005-04-07 |
2008-01-02 |
Chiron Corporation |
Cancer-related genes (prlr)
|
US20070014845A1
(en)
*
|
2005-07-01 |
2007-01-18 |
Yuanpeng Zhang |
Liposomal delivery vehicle for hydrophobic drugs
|
WO2007014169A2
(en)
|
2005-07-22 |
2007-02-01 |
Y's Therapeutics Co, Ltd. |
Anti-cd26 antibodies and methods of use thereof
|
US20070055199A1
(en)
|
2005-08-10 |
2007-03-08 |
Gilbert Scott J |
Drug delivery device for buccal and aural applications and other areas of the body difficult to access
|
ES2664421T3
(es)
|
2005-11-14 |
2018-04-19 |
Teva Pharmaceuticals International Gmbh |
Anticuerpo antagonista dirigido contra un péptido relacionado con el gen de la calcitonina
|
CA2631014C
(en)
*
|
2005-11-28 |
2015-04-28 |
Vernon D. Rowe |
Compositions useful for reducing nephrotoxicity and methods of use thereof
|
US7658913B2
(en)
*
|
2005-11-28 |
2010-02-09 |
Verrow Pharmaceuticals, Inc. |
Compositions useful for reducing nephrotoxicity and methods of use thereof
|
KR100793824B1
(ko)
|
2006-03-06 |
2008-01-11 |
(주)아모레퍼시픽 |
하이드록시프로필-베타사이클로 덱스트린을 이용하여가용화된 유용성 생리활성성분을 담지하는 고분자-리포좀나노복합체
|
NL2000464C2
(nl)
*
|
2006-02-02 |
2007-09-11 |
Rinat Neuroscience Corp |
Werkwijzen voor het behandelen van ongewenst gewichtsverlies of eetstoornissen door het toedienen van een TRKB-agonist.
|
US7935342B2
(en)
*
|
2006-02-02 |
2011-05-03 |
Rinat Neuroscience Corp. |
Methods for treating obesity by administering a trkB antagonist
|
CA2652703C
(en)
|
2006-06-07 |
2018-08-28 |
Bioalliance C.V. |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
ATE522541T1
(de)
|
2006-06-09 |
2011-09-15 |
Novartis Ag |
Bakterielle adhäsine konformere
|
EP2586790A3
(en)
|
2006-08-16 |
2013-08-14 |
Novartis AG |
Immunogens from uropathogenic Escherichia coli
|
US20100261640A1
(en)
|
2007-04-10 |
2010-10-14 |
Branco Luis M |
Soluble and membrane anchored forms of lassa virus subunit proteins
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
EP2231705A2
(en)
|
2007-12-17 |
2010-09-29 |
Pfizer Limited |
Treatment of interstitial cystitis
|
AU2008338313B2
(en)
|
2007-12-18 |
2014-01-16 |
Bioalliance C.V. |
Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
|
US20090196918A1
(en)
*
|
2008-02-01 |
2009-08-06 |
University Of Kentucky Research Foundation |
Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions
|
EP2274437B1
(en)
|
2008-04-10 |
2015-12-23 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting egfr mutations in cancer
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
US9492417B2
(en)
|
2008-08-21 |
2016-11-15 |
The Johns Hopkins University |
Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9拮抗劑類
|
PE20120169A1
(es)
*
|
2008-11-17 |
2012-02-29 |
Genentech Inc |
Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
EP3549602A1
(en)
|
2009-03-06 |
2019-10-09 |
GlaxoSmithKline Biologicals S.A. |
Chlamydia antigens
|
PE20120923A1
(es)
|
2009-03-30 |
2012-08-27 |
Eisai Randd Man Co Ltd |
Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo
|
EP2415464B1
(en)
|
2009-03-30 |
2017-05-10 |
Eisai R&D Management Co., Ltd. |
Method for producing liposome composition
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
SI2510947T1
(sl)
|
2009-04-14 |
2016-05-31 |
Glaxosmithkline Biologicals S.A. |
Sestavki za imunizacijo proti Staphylococcus aureus
|
CN102458114A
(zh)
|
2009-05-29 |
2012-05-16 |
锡德克斯药物公司 |
包含环糊精衍生物的可注射美法仑组合物及其制备和使用方法
|
US11020363B2
(en)
|
2009-05-29 |
2021-06-01 |
Cydex Pharmaceuticals, Inc. |
Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
JP2012532626A
(ja)
|
2009-07-16 |
2012-12-20 |
ノバルティス アーゲー |
無毒化されたEscherichiacoli免疫原
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
SA114360064B1
(ar)
|
2010-02-24 |
2016-01-05 |
رينات نيوروساينس كوربوريشن |
طرق وأجسام مضادة معارضة ضد مستقبل il-7
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2011111007A2
(en)
|
2010-03-11 |
2011-09-15 |
Rinat Neuroscience Corporation |
ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
US9186642B2
(en)
|
2010-04-28 |
2015-11-17 |
The Procter & Gamble Company |
Delivery particle
|
US9993793B2
(en)
|
2010-04-28 |
2018-06-12 |
The Procter & Gamble Company |
Delivery particles
|
US9770414B2
(en)
*
|
2010-05-13 |
2017-09-26 |
Pacira Pharmaceuticals, Inc. |
Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
|
EP2598126A2
(en)
|
2010-07-30 |
2013-06-05 |
Saint Louis University |
Methods of treating pain
|
EP2632553B1
(en)
|
2010-10-28 |
2020-01-01 |
Pacira Pharmaceuticals, Inc. |
A sustained release formulation of a non-steroidal anti-inflammatory drug
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
WO2012118796A1
(en)
|
2011-02-28 |
2012-09-07 |
The Schepens Eye Research Institute, Inc. |
Compositions for controlling neuronal outgrowth
|
CN103458858B
(zh)
|
2011-04-07 |
2016-04-27 |
宝洁公司 |
具有增强的聚丙烯酸酯微胶囊的沉积的洗发剂组合物
|
US8980292B2
(en)
|
2011-04-07 |
2015-03-17 |
The Procter & Gamble Company |
Conditioner compositions with increased deposition of polyacrylate microcapsules
|
JP6283607B2
(ja)
|
2011-04-07 |
2018-02-21 |
ザ プロクター アンド ギャンブル カンパニー |
ポリアクリレートマイクロカプセルの堆積が増大されたパーソナルクレンジング組成物
|
US20130071375A1
(en)
|
2011-08-22 |
2013-03-21 |
Saint Louis University |
Compositions and methods for treating inflammation
|
WO2013028527A1
(en)
|
2011-08-23 |
2013-02-28 |
Indiana University Research And Technology Corporation |
Compositions and methods for treating cancer
|
EP2776470A2
(en)
|
2011-11-11 |
2014-09-17 |
Rinat Neuroscience Corporation |
Antibodies specific for trop-2 and their uses
|
US9249224B2
(en)
|
2011-12-22 |
2016-02-02 |
Rinat Neuroscience Corp. |
Human growth hormone receptor antagonist antibodies and methods of use thereof
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
WO2013168167A1
(en)
|
2012-05-10 |
2013-11-14 |
Painreform Ltd. |
Depot formulations of a hydrophobic active ingredient and methods for preparation thereof
|
ES2651113T3
(es)
|
2012-06-25 |
2018-01-24 |
The Brigham And Women's Hospital, Inc. |
Tratamientos terapéuticos dirigidos
|
JP6246199B2
(ja)
|
2012-07-02 |
2017-12-13 |
ザ ヘンリー エム. ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド |
パラミクソウイルスおよび使用方法
|
MX2015000813A
(es)
*
|
2012-07-18 |
2015-09-07 |
Onyx Therapeutics Inc |
Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
MX2015005874A
(es)
|
2012-11-09 |
2015-09-10 |
Pfizer |
Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
|
EP2968470B1
(en)
|
2013-03-12 |
2020-10-28 |
The General Hospital Corporation |
Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases
|
CN105051068A
(zh)
|
2013-03-15 |
2015-11-11 |
戴埃克斯有限公司 |
抗血浆激肽释放酶抗体
|
MX2015015339A
(es)
|
2013-05-07 |
2016-07-15 |
Rinat Neuroscience Corp |
Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos.
|
US20170172922A1
(en)
*
|
2013-05-15 |
2017-06-22 |
Hsu-Shen WU |
Micron taiwanofungus camphoratus liposome structure
|
TWM473835U
(zh)
*
|
2013-05-15 |
2014-03-11 |
Wu xu sheng |
微米牛樟芝微脂載體結構
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
RU2675516C2
(ru)
|
2013-08-02 |
2018-12-19 |
Пфайзер Инк. |
Anti-cxcr4 антитела и конъюгаты антитело-лекарство
|
SG10201810298VA
(en)
|
2013-11-13 |
2018-12-28 |
Pfizer |
Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
DK3079712T3
(da)
|
2013-12-11 |
2022-04-25 |
Massachusetts Gen Hospital |
Anvendelse af müllersk inhiberende substans- (mis) proteiner til kontraception og ovariereservebevarelse
|
WO2015108932A1
(en)
*
|
2014-01-14 |
2015-07-23 |
The Johns Hopkins University |
Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
DK3119431T3
(da)
|
2014-03-21 |
2024-03-18 |
Teva Pharmaceuticals Int Gmbh |
Antagonistantistoffer rettet mod calcitoningen-relateret peptid og fremgangsmåder til anvendelse deraf
|
US10308697B2
(en)
|
2014-04-30 |
2019-06-04 |
President And Fellows Of Harvard College |
Fusion proteins for treating cancer and related methods
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
US9758575B2
(en)
|
2015-04-06 |
2017-09-12 |
Yung Shin Pharmaceutical Industrial Co. Ltd. |
Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
|
CN114773476A
(zh)
|
2015-04-13 |
2022-07-22 |
辉瑞公司 |
治疗性抗体和它们的用途
|
TWM513697U
(zh)
*
|
2015-06-26 |
2015-12-11 |
Ma Shen Kai Ruei Co Ltd |
仿生物間質系統的載體結構
|
MX2018000714A
(es)
|
2015-07-21 |
2019-11-18 |
Dyax Corp |
Un inhibidor de anticuerpo monoclonal de factor xiia.
|
WO2017015334A1
(en)
|
2015-07-21 |
2017-01-26 |
Saint Louis University |
Compositions and methods for diagnosing and treating endometriosis-related infertility
|
CA3025896A1
(en)
|
2015-07-23 |
2017-01-26 |
The Regents Of The University Of California |
Antibodies to coagulation factor xia and uses thereof
|
PE20240142A1
(es)
|
2015-08-19 |
2024-02-01 |
Pfizer |
Anticuerpos inhibidores via del factor tisular y usos de los mismos
|
LT3350220T
(lt)
|
2015-09-15 |
2021-09-27 |
Scholar Rock, Inc. |
Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
|
KR20180064541A
(ko)
|
2015-10-23 |
2018-06-14 |
화이자 인코포레이티드 |
항-il-2 항체 및 조성물 및 이의 용도
|
WO2017075037A1
(en)
|
2015-10-27 |
2017-05-04 |
Scholar Rock, Inc. |
Primed growth factors and uses thereof
|
EP3370712A4
(en)
|
2015-11-06 |
2019-10-09 |
The Johns Hopkins University |
METHODS OF TREATING HEPATIC FIBROSIS BY ADMINISTERING 3-BROMOPYRUVATE
|
CN106699889A
(zh)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技(上海)有限公司 |
抗pd-1抗体及其治疗用途
|
EP3397287A1
(en)
|
2015-12-30 |
2018-11-07 |
Genentech, Inc. |
Formulations with reduced degradation of polysorbate
|
RU2744860C2
(ru)
|
2015-12-30 |
2021-03-16 |
Кодиак Сайенсиз Инк. |
Антитела и их конъюгаты
|
US10221242B2
(en)
|
2016-01-21 |
2019-03-05 |
Pfizer Inc. |
Antibodies specific for epidermal growth factor receptor variant III and their uses
|
CN109983013A
(zh)
|
2016-11-18 |
2019-07-05 |
帕西拉制药有限公司 |
美洛昔康锌复合物微粒多囊脂质体制剂及其制备方法
|
KR20190124753A
(ko)
|
2017-03-03 |
2019-11-05 |
리나트 뉴로사이언스 코프. |
항-gitr 항체 및 이의 사용 방법
|
WO2018167621A1
(en)
|
2017-03-16 |
2018-09-20 |
Pfizer Inc. |
Tyrosine prototrophy
|
AU2018250695A1
(en)
|
2017-04-14 |
2019-11-07 |
Kodiak Sciences Inc. |
Complement factor D antagonist antibodies and conjugates thereof
|
EP3630841A1
(en)
|
2017-06-02 |
2020-04-08 |
Pfizer Inc. |
Antibodies specific for flt3 and their uses
|
WO2018231771A1
(en)
|
2017-06-13 |
2018-12-20 |
Bostongene Corporation |
Systems and methods for generating, visualizing and classifying molecular functional profiles
|
WO2019016784A1
(en)
|
2017-07-21 |
2019-01-24 |
Universidade De Coimbra |
ANTI-NUCLEOLIN ANTIBODIES
|
CA3078460A1
(en)
|
2017-10-04 |
2019-04-11 |
Opko Pharmaceuticals, Llc |
Articles and methods directed to personalized therapy of cancer
|
EP3706801A4
(en)
*
|
2017-11-08 |
2022-04-06 |
L.E.A.F Holdings Group LLC |
PLATINUM COMPLEXES AND THEIR USES
|
US11377500B2
(en)
|
2018-02-01 |
2022-07-05 |
Pfizer Inc. |
Antibodies specific for CD70 and their uses
|
JP7404247B2
(ja)
|
2018-02-01 |
2023-12-25 |
ファイザー・インク |
Cd70を標的とするキメラ抗原受容体
|
CA3034912A1
(en)
|
2018-02-28 |
2019-08-28 |
Pfizer Inc. |
Il-15 variants and uses thereof
|
EP3796983A2
(en)
|
2018-05-23 |
2021-03-31 |
Pfizer Inc. |
Antibodies specific for gucy2c and uses thereof
|
TWI793325B
(zh)
|
2018-05-23 |
2023-02-21 |
美商輝瑞大藥廠 |
對cd3具特異性之抗體及其用途
|
IL281217B1
(en)
*
|
2018-09-14 |
2024-01-01 |
Pharmosa Biopharm Inc |
Pharmaceutical preparation for controlled release of weak acid drugs and its uses
|
JP2022518147A
(ja)
|
2019-01-03 |
2022-03-14 |
アンダードッグ・ファーマシューティカルズ・インコーポレイテッド |
シクロデキストリン二量体、それらの組成物、及びそれらの使用
|
EP3994696A2
(en)
|
2019-07-03 |
2022-05-11 |
BostonGene Corporation |
Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control
|
US11083705B2
(en)
|
2019-07-26 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
WO2021071830A1
(en)
|
2019-10-07 |
2021-04-15 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
WO2021072244A1
(en)
|
2019-10-11 |
2021-04-15 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-tn antibodies and uses thereof
|
WO2021151079A1
(en)
|
2020-01-24 |
2021-07-29 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
WO2021205325A1
(en)
|
2020-04-08 |
2021-10-14 |
Pfizer Inc. |
Anti-gucy2c antibodies and uses thereof
|
US20230181750A1
(en)
|
2020-05-06 |
2023-06-15 |
Crispr Therapeutics Ag |
Mask peptides and masked anti-ptk7 antibodies comprising such
|
TW202216779A
(zh)
|
2020-07-17 |
2022-05-01 |
美商輝瑞股份有限公司 |
治療性抗體類和彼等之用途
|
US20230287455A1
(en)
|
2020-07-30 |
2023-09-14 |
Pfizer Inc. |
Cells Having Gene Duplications and Uses Thereof
|
AU2021338361A1
(en)
|
2020-09-03 |
2023-04-06 |
Chen, Irvin S.Y |
Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
|
CN112190498B
(zh)
*
|
2020-10-31 |
2022-03-25 |
华南理工大学 |
一种具有水溶性的茶碱和环糊精包合物及其制备方法
|
US20240029829A1
(en)
|
2020-12-04 |
2024-01-25 |
Bostongene Corporation |
Hierarchical machine learning techniques for identifying molecular categories from expression data
|
US11357727B1
(en)
|
2021-01-22 |
2022-06-14 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11278494B1
(en)
|
2021-01-22 |
2022-03-22 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11033495B1
(en)
|
2021-01-22 |
2021-06-15 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
WO2022232615A1
(en)
|
2021-04-29 |
2022-11-03 |
Bostongene Corporation |
Machine learning techniques for estimating tumor cell expression complex tumor tissue
|
CA3227875A1
(en)
|
2021-08-02 |
2023-02-09 |
Pfizer Inc. |
Improved expression vectors and uses thereof
|
US20230245479A1
(en)
|
2022-01-31 |
2023-08-03 |
Bostongene Corporation |
Machine learning techniques for cytometry
|
WO2023148598A1
(en)
|
2022-02-02 |
2023-08-10 |
Pfizer Inc. |
Cysteine prototrophy
|
WO2024015561A1
(en)
|
2022-07-15 |
2024-01-18 |
Bostongene Corporation |
Techniques for detecting homologous recombination deficiency (hrd)
|